BUNGA CANTIKA, - (2025) ANALISIS EFEKTIVITAS BIAYA PENGOBATAN DIABETES MELITUS TIPE 2 DENGAN PENYAKIT PENYERTA KOLESTEROL PADA PASIEN RAWAT JALAN DI RSUD WELAS ASIH PROVINSI JAWA BARAT. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.
![[img]](http://repository.stfi.ac.id/style/images/fileicons/text.png) |
Text
S_PSSF_A233003_Title.pdf Download (1MB) |
|
Text
S_PSSF_A233003_Chapter1.pdf Restricted to Repository staff only Download (222kB) |
|
Text
S_PSSF_A233003_Chapter2.pdf Restricted to Repository staff only Download (338kB) |
|
Text
S_PSSF_A233003_Chapter3.pdf Restricted to Repository staff only Download (275kB) |
|
Text
S_PSSF_A233003_Chapter4.pdf Restricted to Repository staff only Download (319kB) |
|
Text
S_PSSF_A233003_Chapter5.pdf Restricted to Repository staff only Download (166kB) |
|
Text
S_PSSF_A233003_Appendix.pdf Restricted to Repository staff only Download (973kB) |
Abstract
Diabetes merupakan penyakit tidak menular yang cukup serius dimana pankreas tidak dapat memproduksi insulin secara optimal. Hubungan antara dislipidemia dengan diabetes melitus (DM) tipe 2 bersifat timbal balik. Dislipidemia dapat mempengaruhi resistensi insulin yang kemudian dapat menyebabkan gangguan metabolisme glukosa dan akhirnya menyebabkan diabetes melitus tipe 2. Penelitian ini bertujuan untuk mengetahui biaya terapi yang paling efektif (cost-effectiveness) dan faktor-faktor apa saja yang mempengaruhi efektivitas biaya terapi obat antidiabetes pada pasien diabetes melitus tipe 2 dengan penyakit penyerta kolesterol di RSUD Welas Asih Provinsi Jawa Barat. Metode dalam penelitian ini menggunakan desain retrospektif dengan pengambilan data dari rekam medis dan rincian biaya medis langsung pasien secara purposive sampling di RSUD Welas Asih Provinsi Jawa Barat periode JanuariDesember 2024. Analisis efektivitas biaya dilakukan menggunakan Average Cost Effectiveness Ratio (ACER), Incremental Cost Effectiveness Ratio (ICER), dan analisis sensitivitas. Hasil menunjukkan bahwa metformin memberikan penurunan kadar gula darah sewaktu yang lebih tinggi dengan rata-rata 73,05 mg/dL, sedangkan glimepirid hanya sebesar 34,5 mg/dL. Dan diperoleh nilai ACER metformin sebesar Rp. 19.055,44 lebih rendah dibandingkan ACER glimepirid sebesar Rp. 40.953,04, sehingga dapat disimpulkan bahwa metformin dinilai lebih efisien dibandingkan glimepirid. Efektivitas biaya ini dipengaruhi oleh beberapa faktor, seperti harga obat, biaya pemeriksaan laboratorium, dan konsultasi dokter. ----- Diabetes is a serious non-communicable disease in which the pancreas cannot produce insulin optimally. The relationship between dyslipidemia and type 2 diabetes mellitus (DM) is reciprocal. Dyslipidemia can affect insulin resistance, which can then cause glucose metabolism disorders and ultimately lead to type 2 diabetes mellitus. This study aims to determine the most cost-effective therapy and what factors influence the costeffectiveness of antidiabetic drug therapy in patients with type 2 diabetes mellitus with comorbid cholesterol at Welas Asih Regional Hospital, West Java Province. The method in this study used a retrospective design with data retrieval from medical records and details of direct medical costs of patients by purposive sampling at Welas Asih Regional Hospital, West Java Province for the period January-December 2024. Cost-effectiveness analysis was conducted using the Average Cost-Effectiveness Ratio (ACER), Incremental Cost-Effectiveness Ratio (ICER), and sensitivity analysis. The results showed that metformin provided a higher reduction in random blood sugar levels with an average of 73.05 mg/dL, while glimepiride only 34.5 mg/dL. And the ACER value of metformin was Rp. 19,055.44 lower than the ACER of glimepiride of Rp. 40,953.04, so it can be concluded that metformin is considered more efficient than glimepiride. This cost-effectiveness is influenced by several factors, such as drug price, laboratory examination costs, and doctor consultations.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Uncontrolled Keywords: | Analisis Efektivitas Biaya, Diabetes Melitus Tipe 2, Dislipidemia, Glimepirid, Metformin. ----- Cost Effectiveness Analysis, Dyslipidemia, Glimepiride, Metformin, Type 2 Diabetes Mellitus. |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine |
| Divisions: | Program Studi S1 Farmasi |
| Depositing User: | pustakawan - - |
| Date Deposited: | 30 Aug 2025 01:46 |
| Last Modified: | 30 Aug 2025 01:46 |
| URI: | http://repository.stfi.ac.id/id/eprint/2724 |
Actions (login required)
 |
View Item |
